 |
인쇄하기
취소
|
VGX Pharmaceuticals grants VGX International to exclusive license for VGX-1027
VGX International announced on February 28 it has granted VGX International an exclusive license to its VGX-1027, lead drug candidate for the treatment of rheumatoid arthritis (RA) and type 1 diabetes (T1D).
VGX-1027 is a novel orally-active, small-molecule compound with broad anti-inflammatory properties.
Under the agreement, VGX International will have an additional exclusive right ma...
VGX-1027 is a novel orally-active, small-molecule compound with broad anti-inflammatory properties.
Under the agreement, VGX International will have an additional exclusive right ma...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.